214 related articles for article (PubMed ID: 12889738)
1. Use of positron emission tomography in anticancer drug development.
Aboagye EO; Price PM
Invest New Drugs; 2003 May; 21(2):169-81. PubMed ID: 12889738
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, biodistribution and micro-PET imaging of radiolabeled antimitotic agent T138067 analogues.
Fei X; Zheng QH; Wang JQ; Stone KL; Martinez TD; Miller KD; Sledge GW; Hutchins GD
Bioorg Med Chem Lett; 2004 Mar; 14(5):1247-51. PubMed ID: 14980675
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography (PET): expanding the horizons of oncology drug development.
Hammond LA; Denis L; Salman U; Jerabek P; Thomas CR; Kuhn JG
Invest New Drugs; 2003 Aug; 21(3):309-40. PubMed ID: 14578681
[TBL] [Abstract][Full Text] [Related]
4. [Biomedical imaging in pharmacology with nuclear medical imaging methodologies: positron emission tomography (PET) and single photon emission computed tomography (SPECT)].
Saji H; Iida Y
Nihon Yakurigaku Zasshi; 2003 Mar; 121(3):181-91. PubMed ID: 12673952
[TBL] [Abstract][Full Text] [Related]
5. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography.
Picchio M; Messa C; Landoni C; Gianolli L; Sironi S; Brioschi M; Matarrese M; Matei DV; De Cobelli F; Del Maschio A; Rocco F; Rigatti P; Fazio F
J Urol; 2003 Apr; 169(4):1337-40. PubMed ID: 12629355
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development.
Bergström M; Grahnén A; Långström B
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):357-66. PubMed ID: 12937873
[TBL] [Abstract][Full Text] [Related]
7. What does positron emission tomography offer oncology?
Anderson H; Price P
Eur J Cancer; 2000 Oct; 36(16):2028-35. PubMed ID: 11044638
[TBL] [Abstract][Full Text] [Related]
8. Single photon emission computed tomography and positron emission tomography in cancer imaging.
Coleman RE
Cancer; 1991 Feb; 67(4 Suppl):1261-70. PubMed ID: 1991287
[TBL] [Abstract][Full Text] [Related]
9. Applications of positron emission tomography in the development of molecular targeted cancer therapeutics.
Solomon B; McArthur G; Cullinane C; Zalcberg J; Hicks R
BioDrugs; 2003; 17(5):339-54. PubMed ID: 14498764
[TBL] [Abstract][Full Text] [Related]
10. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group.
Price P; Jones T
Eur J Cancer; 1995 Nov; 31A(12):1924-7. PubMed ID: 8562143
[TBL] [Abstract][Full Text] [Related]
11. Instrumentation in positron emission tomography. Council on Scientific Affairs. Report of the Positron Emission Tomography Panel.
JAMA; 1988 Mar; 259(10):1531-6. PubMed ID: 3257530
[TBL] [Abstract][Full Text] [Related]
12. The role of PET scanning in determining pharmacoselective doses in oncology drug development.
Price P
Ernst Schering Res Found Workshop; 2007; (59):185-93. PubMed ID: 17117724
[TBL] [Abstract][Full Text] [Related]
13. 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337.
Wells P; Aboagye E; Gunn RN; Osman S; Boddy AV; Taylor GA; Rafi I; Hughes AN; Calvert AH; Price PM; Newell DR
J Natl Cancer Inst; 2003 May; 95(9):675-82. PubMed ID: 12734319
[TBL] [Abstract][Full Text] [Related]
14. The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals.
Roselt P; Meikle S; Kassiou M
Eur J Drug Metab Pharmacokinet; 2004; 29(1):1-6. PubMed ID: 15151164
[TBL] [Abstract][Full Text] [Related]
15. Combination of positron emission tomography with liquid chromatography in neuropharmacologic research.
Hartvig P; Långström B
J Chromatogr; 1990 May; 507():303-10. PubMed ID: 2199473
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of 18F-fluorodeoxyglucose positron emission tomography in lymphoma.
Weihrauch MR; Dietlein M; Schicha H; Diehl V; Tesch H
Leuk Lymphoma; 2003 Jan; 44(1):15-22. PubMed ID: 12691138
[TBL] [Abstract][Full Text] [Related]
17. Impact of technology on the utilisation of positron emission tomography in lymphoma: current and future perspectives.
Visvikis D; Ell PJ
Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S106-16. PubMed ID: 12748830
[TBL] [Abstract][Full Text] [Related]
18. Functional PET imaging in cancer drug development.
Avril N; Propper D
Future Oncol; 2007 Apr; 3(2):215-28. PubMed ID: 17381421
[TBL] [Abstract][Full Text] [Related]
19. Introduction to imaging brain tumor metabolism with positron emission tomography (PET).
Conti PS
Cancer Invest; 1995; 13(2):244-59. PubMed ID: 7874578
[TBL] [Abstract][Full Text] [Related]
20. Current status of positron emission tomography in oncology.
Scott AM
Australas Radiol; 2002 Jun; 46(2):154-62. PubMed ID: 12060153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
